Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases. Its products include Truvada, Viread, Atripla, and Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, amphotericin B liposome injection to treat serious invasive fungal infections; Flolan, an injected medication for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension; and Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS). The company also offers Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular age-related macular degeneration; and DaunoXome, a liposomal formulation of the anticancer agent daunorubicin for the treatment of AIDS-related Kaposi’s sarcoma. Gilead Sciences markets its products in the United States, Australia, Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Portugal, Spain, Switzerland, Turkey, and the United Kingdom. The company has research collaborations with Japan Tobacco, Inc.; Achillion Pharmaceuticals, Inc.; Genelabs Technologies, Inc.; Novartis Vaccines and Diagnostics, Inc.; GlaxoSmithKline, Inc.; Novartis Institutes for BioMedical Research, Inc.; Abbott Laboratories, Inc.; and University of Texas System. It also has commercial collaborations with Emory University; Bristol-Myers Squibb Company; OSI Pharmaceuticals, Inc.; Pfizer, Inc.; Dainippon Sumitomo Pharma Co., Ltd.; F. Hoffmann-La Roche, Ltd.; M.D. Anderson Cancer Center; Astellas Pharma, Inc.; and University License Equity Holdings, Inc. The company was founded in 1987 and is headquartered in Foster City, California.